CytoDyn Files for FDA Breakthrough Therapy Status for Leronlimab for Metastatic TNBC
News
CytoDyn has requested breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy leronlimab (PRO 140) as an adjuvant treatment for metastatic triple-negative breast cancer (TNBC). ... Read more